1528-P: Identifying Nutrient Associated with Coronary Heart Disease Risk in Male Patients with Type 2 Diabetes Using a Subgroup Detection Approach

Introduction and Objective: Dietary management for type 2 diabetes is based on evidence demonstrating improvements in surrogate outcomes such as blood glucose, blood pressure, and serum lipids. However, there is limited evidence using the onset of complications themselves as an outcome. Furthermore, as nutrients and dietary patterns are intricately interrelated, conventional statistical analysis methods have limitations. This study aimed to identify nutrients associated with the risk of coronary heart disease (CHD) in a cohort of type 2 diabetes patients through the use of AI. Methods: We analyzed male patients with type 2 diabetes enrolled in the JDCS and J-EDIT cohorts, among whom 59 coronary heart disease (CHD) events were observed. Using a subgroup detection approach incorporating principal component analysis (PCA), linear regression, and Wilcoxon’s rank-sum test, we identified a latent subgroup characterized by an association between nutrient intake and CHD risk. PCA was subsequently reapplied to this subgroup to define a high-risk population. Finally, CHD incidence was compared between the high- and low-risk groups using Kaplan-Meier survival curves, the log-rank test, and hazard ratios (HRs). Results: A subgroup characterized by insufficient intake of potassium, vitamin B6, etc. was identified. Within this subgroup, excessive intake of protein, vitamin B1, etc. was associated with an elevated risk of CHD. The high-risk group demonstrated a significantly higher incidence of CHD events (P = 0.024; HR = 4.90; 95% CI, 1.06-22.66). Conclusion: Analysis using artificial intelligence has facilitated the identification of high-risk groups through complex combinations of conditions. In men with type 2 diabetes who are deficient in potassium, vitamin B6, and other nutrients, excessive intake of protein and vitamin B1 may be associated with an increased risk of coronary heart disease (CHD). Disclosure M. Takeuchi: Research Support; Current; NEC Solution Innovators, Ltd., Tokyo, Japan. C. Horikawa: None. K. Fujihara: None. T. Suzuki: Employee; Ended; Siemens Healthcare K.K. Employee; Current; NEC Solution Innovators, Ltd. K. Koike: Employee; Current; NEC Solution Innovators, Ltd. K. Yasuda: Employee; Current; NEC Solution Innovators, Ltd. C. Kamada: None. Y. Yoshimura: None. S. Tanaka: None. A. Araki: Speaker's Bureau; Current; Novo Nordisk. Speaker's Bureau; Ended; Sumitomo Dainippon Pharma Co., Ltd. S. Kato: Employee; Current; NEC Solution Innovators, Ltd. H. Sone: None.